Physical activity, even at moderate levels, reduces the risk of incident and recurrent myocardial infarction, independently of the exposure to NO2.
The CARMELINA trial, evaluating long-term safety outcomes of DPP-4 inhibitor linagliptin vs placebo in T2DM adults, many of whom had kidney disease, met its primary endpoint, showing CV safety.
In primary prevention of CV events, low-dose aspirin was effective mainly in individuals weighing <70 kg, and higher doses of aspirin were of benefit for patients weighing ≥70 kg.
Black individuals have a significantly higher risk for hypertension compared with whites, from young adulthood through middle age, irrespective of BP before the age of 30 years.
EPCCS 2018 Management of heart failure is complex, as it often concerns elderly patients who have comorbidities. Good cooperation between primary and secondary care can benefit these patients.
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents
Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.
In a subanalysis of the ACCORD BP trial, intensive blood pressure treatment in T2DM patients receiving standard glycemic control was significantly associated with a decreased risk of CV events, including HF hospitalization.
A prospective study showed an inversed association between nut consumption and incidence of atrial fibrillation and heart failure in the Swedish population.
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
Maintaining or changing to a healthy lifestyle after diabetes diagnosis is associated with a significantly lower risk CVD incidence and mortality.